Costa News Spain Breaking News | English News in Spain.
Weight-loss seekers are warned that a possible side effect from drugs like Ozempic is a sudden blindness.
The European Medicines Agency (EMA) has told Danish manufacturer Novo Nordisk to highlight this possible side effect on the packaging.
In particular, consumers may be at risk of an ischemic condition known in medical terms as NAION (non arterial ischemic optical neuropathy).
Ozempic is a semaglutide-based medication – and while this has been credited for its miraculous outcomes, the presence of it may cause the sudden loss of eyesight.
READ MORE: Ozempic manufacturer in trouble for ‘very obviously’ advertising prescription-only drug in Spain
Semaglutide mimics a hormone called GLP-1 that is naturally produced by the body. This hormone has several effects that have led Ozempic to be dubbed a ‘miracle drug’, including regulating blood sugar, slowing down digestion and reducing appetite.
It is important to note that statistically, only 0.04% patients who receive semaglutide will be affected.
There are three main semaglutide-based medications currently on the market – all manufactured by Novo Nordisk.
READ MORE: Ozempic manufacturer facing backlash in Spain for ‘obesity can kill’ campaign
They include Ozempic, an injectable medication actually primarily prescribed for Type 2 diabetes, and Wegovy, another injectable with a higher dose of semaglutide – this one specifically for chronic weight management.
Rybelsus tablet is also used in Type 2 Diabetes.
Fernando Gerchman, a Brazilian endocrinologist and lead author of the latest study published this month by vision loss research group JAMA Opthalmology said that ‘the findings confirm a signal, but the results need to be replicated.’
In July 2024 research connected NAION to the consumption of semaglutide. Gerchman’s more recent report has further strengthened this thesis – but more research is needed.
The EMA advised this summer that all information regarding Ozempic medicines in product sheets, packaging leaflets, and medicine labels be updated so consumers are aware.
The Committee for Medicinal Products for Human Use of the EMA (CHMP) has yet to ratify this.
Health agencies have raised a number of concerns and controversies about the controversial drug, warning of its possible side effects.
Click here to read the latest Spain News at The Olive Press.
